Allergan and Gedeon Richter announced positive topline results for a phase 3 study of cariprazine for the treatment of adults with major depressive episodes associated with bipolar I disorder. This is the second positive pivotal trial of cariprazine for this investigational use.    In this study, the primary efficacy objective was met for both Cariprazine 1.5mg and 3mg dose groups. Both showed a significantly greater improvement than placebo for the change from baseline to week 6 on the ...